Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics


Ultragenyx Pharmaceutical Inc. (RARE): $78.22

-0.18 (-0.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RARE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

RARE POWR Grades


  • RARE scores best on the Value dimension, with a Value rank ahead of 66.27% of US stocks.
  • The strongest trend for RARE is in Growth, which has been heading down over the past 52 weeks.
  • RARE ranks lowest in Sentiment; there it ranks in the 7th percentile.

RARE Stock Summary

  • The ratio of debt to operating expenses for Ultragenyx Pharmaceutical Inc is higher than it is for about merely 10.84% of US stocks.
  • RARE's price/sales ratio is 14.8; that's higher than the P/S ratio of 87.46% of US stocks.
  • Revenue growth over the past 12 months for Ultragenyx Pharmaceutical Inc comes in at 125.44%, a number that bests 94.55% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Ultragenyx Pharmaceutical Inc, a group of peers worth examining would be SLDB, RGNX, EDIT, MTEM, and DRNA.
  • RARE's SEC filings can be seen here. And to visit Ultragenyx Pharmaceutical Inc's official web site, go to www.ultragenyx.com.

RARE Valuation Summary

  • In comparison to the median Healthcare stock, RARE's EV/EBIT ratio is 161.43% lower, now standing at -18.
  • RARE's price/earnings ratio has moved up 5 over the prior 92 months.
  • Over the past 92 months, RARE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RARE.

Stock Date P/S P/B P/E EV/EBIT
RARE 2021-08-31 18.2 6.7 -18.6 -18.0
RARE 2021-08-30 18.1 6.7 -18.5 -17.9
RARE 2021-08-27 17.7 6.6 -18.1 -17.5
RARE 2021-08-26 17.0 6.3 -17.4 -16.7
RARE 2021-08-25 17.0 6.3 -17.4 -16.8
RARE 2021-08-24 16.5 6.1 -16.9 -16.2

RARE Growth Metrics

  • Its 3 year price growth rate is now at -1.54%.
  • Its year over year net cashflow from operations growth rate is now at 43.03%.
  • Its 3 year net income to common stockholders growth rate is now at -83.41%.
Over the past 15 months, RARE's revenue has gone up $237,531,000.

The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 359.382 -349.121 -351.425
2021-03-31 334.116 -196.414 -203.682
2020-12-31 271.03 -132.22 -186.566
2020-09-30 215.081 -141.807 -256.36
2020-06-30 159.411 -168.346 -300.509
2020-03-31 121.851 -344.76 -424.996

RARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
  • RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
  • ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.

The table below shows RARE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.234 0.955 -0.414
2021-03-31 0.225 0.956 -0.267
2020-12-31 0.194 0.977 -0.277
2020-09-30 0.174 0.973 -0.420
2020-06-30 0.140 0.962 -0.540
2020-03-30 0.116 0.959 -0.769

RARE Price Target

For more insight on analysts targets of RARE, see our RARE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.67 Average Broker Recommendation 1.58 (Moderate Buy)

RARE Stock Price Chart Interactive Chart >

Price chart for RARE

RARE Price/Volume Stats

Current price $78.22 52-week high $179.65
Prev. close $78.40 52-week low $75.83
Day low $75.83 Volume 361,849
Day high $78.62 Avg. volume 489,451
50-day MA $89.76 Dividend yield N/A
200-day MA $107.04 Market Cap 5.31B

Ultragenyx Pharmaceutical Inc. (RARE) Company Bio


Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.


RARE Latest News Stream


Event/Time News Detail
Loading, please wait...

RARE Latest Social Stream


Loading social stream, please wait...

View Full RARE Social Stream

Latest RARE News From Around the Web

Below are the latest news stories about Ultragenyx Pharmaceutical Inc that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,851,310 shares of the biopharmaceutical companys stock after selling 61,098 shares during the period. Ultragenyx Pharmaceutical makes up approximately 0.7% of Federated Hermes Inc.s investment portfolio, making the stock its 18th []

Transcript Daily | October 21, 2021

Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 19, 2021

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

NOVATO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases, today announced that it has successfully screened and enrolled multiple patients with Wilson disease into the baseline monitoring period prior to dosing in its pivotal, seamless Phase 1/2/3 study of UX701, the Cyprus2+ study. The company''s investigational AAV9 gene therapy is designed to deliver stable expression of the ATP7B copper transporter following a single intravenous infusion, with the goal of establishing normal trafficking of copper in patients with Wilson disease. "Through collaboration with the FDA and other regulatory agencies we are able to ...

Benzinga | October 18, 2021

Hedge Funds Are Piling Into Ultragenyx Pharmaceutical Inc (RARE)

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | October 18, 2021

Ultragenyx Pharmaceutical Insider Sold $550K In Company Stock

Mardi Dier, CFO And Executive Vice President at Ultragenyx Pharmaceutical (NASDAQ:RARE), made a large insider sell on October 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Dier sold 6,738 shares of Ultragenyx Pharmaceutical at prices ranging from $81.16 to $82.79. The total transaction amounted to $552,524. Following the transaction, Dier still owns 38,762 shares of the company, worth $3,127,705. Ultrage

Yahoo | October 15, 2021

Read More 'RARE' Stories Here

RARE Price Returns

1-mo -18.93%
3-mo -5.44%
6-mo -28.81%
1-year -14.89%
3-year 27.02%
5-year 17.80%
YTD -43.49%
2020 224.12%
2019 -1.77%
2018 -6.25%
2017 -34.03%
2016 -37.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.5354 seconds.